A neutropenia suggesting an interaction between valacyclovir and mycophenolate mofetil

Clinical Transplantation

Volumn 17, Issue 2, 2003, Pages 158-161

  Royer, Bernard ^a   Zanetta, Gilbert ^b   Bérard, Michael ^a   Davani, Siamak ^a   Tanter, Yves ^b   Rifle, Gérard ^b   Kantelip, Jean Pierre ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

Acyclovir; Drug interactions; Mycophenoic acid; Neutropenia

Indexed keywords

25 HYDROXYVITAMIN D; ACICLOVIR; ANTIVIRUS AGENT; CALCIUM; CLORAZEPATE DIPOTASSIUM; CYCLOSPORIN A; FUROSEMIDE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; LEVOTHYROXINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; POTASSIUM; PRAVASTATIN; PREDNISOLONE; PROPRANOLOL; RIFAMPICIN; THYMOCYTE ANTIBODY; VALACICLOVIR;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; NEUTROPENIA; PRIORITY JOURNAL; REINFECTION;

ACYCLOVIR; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; MYCOPHENOLIC ACID; NEUTROPENIA; VALINE;

EID: 0037626497     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2003.00052.x     Document Type: Article

References (10)

1. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U S Renal Transplant Mycophenolate Mofetil Study Group Transplantation 1995: 60: 225.
2. Wiesel M, Carl S. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group. J Urol 1998: 159: 28.
3. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999: 340: 1462.
4. Ormrod D, Scott LJ, Perry CM. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs 2000: 59: 839.
5. Jacobson MA, Gallant J, Wang LH et al. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 1994: 38: 1534.
6. Shapiro R, Jordan ML, Scantlebury VP et al. A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. J Urol 1998: 160: 1982.
7. Banerjee R, Halil O, Bain BJ, Cummins D, Banner NR. Neutrophil dysplasia caused by mycophenolate mofetil. Transplantation 2000: 70: 1608.
8. Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS. RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation 1992: 53: 428.
9. Dornsife RE, Averett DR vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob Agents Chemother 1996: 40: 514.
10. Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998: 42: 216.